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Abstract  
Importance of the field 
Osteosarcoma belongs to the orphan diseases but is the most common primary malignant 
tumor of bone. Currently, the standard treatment for osteosarcoma requires both 
macroscopic surgical wide resection and postoperative multi-drug chemotherapy in 
neo-adjuvant and adjuvant settings. However, the 5-year event-free survival remains at a 
plateau of 60-70% of patients with non-metastatic osteosarcoma for over 30 years.  
Areas covered in this review 
Mifamurtide [liposomal muramyl tripeptide phosphatidylethanolamine (L-MTP-PE)] is a 
new agent. L-MTP-PE is a nonspecific immunomodulator, which is a synthetic analog of 
a component of bacterial cell walls. L-MTP-PE activates macrophages and monocytes as 
a potent activator of immune response. The addition of L-MTP-PE to standard 
chemotherapy improves the overall survival from 70 % to 78% and results in a one-third 
reduction in the risk of death from osteosarcoma. 
What the reader will gain 
Recently, L-MTP-PE has been approved in Europe for the treatment of non-metastatic 
osteosarcoma with chemotherapy. According to preliminary clinical report, L-MTP-PE is 
well-tolerated and has little severe side effects.  
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Take home message 
L-MTP-PE in combination with traditional treatment is expected to go mainstream and to 
be beneficial for patients with osteosarcoma. 
Key words osteosarcoma, liposomal muramyl tripeptide 
phosphatidylethanolamine, macrophage, chemotherapy, innate immunity 
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1. Introduction 
Osteosarcoma is the most common primary malignant bone tumor. It usually arises in the 
metaphyses of long bone in children and adolescents [1, 2]. Approximately 1000 new 
patients are seen per year in North America and a similar number in Europe [3]. The 
standard treatment of the primary osteosarcoma consists of microscopically 
complete surgical resection and multi-agent chemotherapy in neo-adjuvant and 
adjuvant settings. Surgical techniques for osteosarcoma have improved and built up 
from amputations to limb-salvage surgery during the last decades [4]. However, it did not 
contribute to the improvement of both EFS and overall survival. 
On the other hand, the value of chemotherapy for treatment of osteosarcoma is 
well established [5, 6]. There are currently four chemotherapeutic agents, which consist 
of doxorubicin, cisplatin, high-dose methotrexate with leucovorin rescue, and ifosfamide 
[7-11]. Vigorous chemotherapy treatment with these agents has significantly improved 
survival of the osteosarcoma patients over the past several decades [12]. It has been 
reported that EFS of osteosarcoma patients at 3-5 years has reached 60-70% in the 
non-metastatic condition. However, in the metastatic relapse or recurrent conditions, 
EFS of osteosarcoma patients at 3-5 years remained at 10-30% since early 1980s [4, 
12-14]. None of the various chemotherapy agents and regimens has demonstrated any 
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significant superiority yet [15]. No new anti-osteosarcoma agents have been developed in 
the intervening years [16]. Recently, Children’s Oncology Group carried out long-term 
follow-up of the key trial of chemotherapy with or without mifamurtide (liposomal 
muramyl tripeptide phosphatidyl ethanolamine [L-MTP-PE]). This group demonstrated 
that addition of L-MTP-PE to chemotherapy significantly improved overall survival at 6 
years from 70% with chemotherapy alone to 78 % with chemotherapy and L-MTP-PE (p 
= 0.03) [17]. These data demonstrate that L-MTP-PE may have a potential role in the 
improvement of survival of the osteosarcoma patients remained on a plateau for over two 
decades [16, 18-20]. The proprietary product name of mifamurtide is Mepact® 
(Takeda). L-MTP-PE, a nonspecific immunomodulator, is a synthetic analog of a 
component of bacterial cell walls [21]. L-MTP-PE activates macrophages and monocytes 
as a potent activator of immune response [22, 23].  
In this review, we will summarize the most recent findings about L-MTP-PE and 
its therapeutic application for non-metastatic osteosarcoma. 
 
2. Pharmacology  
MTP-PE is a stimulator of innate immunity and a synthetic molecule derived from 
muramyl dipeptide (MDP). MTP-PE results from the covalent addition of alanin and 
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dipalmitoyl phosphatidyl ethanolamine to MDP (Figure 1), which is a peptidoglycan 
found in Gram-positive and Gram-negative bacterial cell walls [21].  
In vitro and in vivo monocytes/macrophages activation by MTP-PE is related to 
the upregulation of tumoricidal activity and secretion of pro-inflammatory cytokines 
including tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, IL-8, nitric oxide (NO), 
prostaglandin E2 (PGE2), and PGD2 [24-29]. NO, PGE2, and PGD2 are synthesized and 
released by murine Kupffer cells (liver macrophages) after in vitro MTP-PE exposure 
[30]. Moreover, L-MTP-PE induces the expression of adhesion molecules including 
lymphocyte function-associated antigen (LFA)-1, intracellular adhesion molecule 
(ICAM)-1, and human leukocyte antigen (HLA)-DR. These molecules could be closely 
related to interaction with tumor cells [21, 31]. 
MTP-PE is superior to MDP in the activation of human monocytes [22]. The 
lipophilic MTP-PE could be efficiently incorporated in the lipid bilayer of liposomal 
structures and distributed primarily in the liver, spleen, and lungs after intravenous 
MTP-PE administration [22, 23, 32]. Thus, the intravenous MTP-PE encapsulated in 
liposomes has been developed to target delivery of the drug selectively to monocytes and 
macrophages, such as those in liver, spleen, and lungs [13, 16, 21]. The lipid 
composition of mifamurtide also facilitates macrophage signaling via phosphatidyl 
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serine recognition by macrophages [33]. The particle nature of liposomes converts the 
parent drug into ‘‘pro-drug’’. Liposomes are concentric multi-lamellar vesicles with the 
lipid bilayers resembling an onion of particle size approximately 2-3 µm. Formulation of 
MTP-PE into these phospholipid vesicles enhances the activation of 
macrophages/monocytes tumoricidal properties and extends its existence in the lungs [22, 
32]. In fact, an advantage of MTP-PE over MDP in the activation of human monocytes 
was demonstrated [22]. This advantage was ascribed to the benefit of the lipophilic 
properties of MTP-PE described earlier. In addition, the liposomal formulation 
(L-MTP-PE) has improved the safety profile of several drugs by modifying parent drug or 
solubilization agent toxicity [34]. Due to rapid mononuclear phagocytosis of the 
liposome transporter, L-MTP-PE has very rapid clearance from the blood only 
approximately 0.5% of L-MTP-PE remains in the plasma at the 5-min time point 
compared with 93% when administrated as the free form [35]. In humans, there is no 
evidence of accumulation of either liposomes or free MTP-PE after L-MTP-PE 4-mg 
treatment twice a week for 9 week [36]. The half-life of free MTP-PE can be estimated as 
3-6 h from dog and rat studies. Additionally, no accumulation of phospho1ipids after 
repeated administration has been confirmed [32]. Due to such the rapid clearance, 
L-MTP-PE shows ten times lesser adverse event level than free MTP-PE in rabbits and 
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dogs [21]. 
MTP-PE can bind to Toll-like receptor (TLR) 4 and activate extracellular-signal 
regulated kinase 1/2 (ERK 1/2), nuclear factor-kappa B (NF-κB) and adaptor protein 
(AP)-1 [29, 37]. However, the other receptor for MTP-PE may be intracellular [22]. 
Recently, MTP-PE has been reported as a specific ligand of nucleotide-binding 
oligomerization domain (Nod) 2 receptor. Nod2, an intracellular MDP sensor, is strongly 
expressed in monocytes, granulocytes, myeloid dendritic cells, and macrophages [38]. It 
induces NF-κB and influences the innate immune response   [39]. L-MTP-PE is 
selectively phagocytosed by monocytes and macrophages after intravenous 
administration [40]. The phagocytic cells gradually degrade the liposomal vesicles. Then, 
MTP-PE is released into the cytosol and is degraded to MDP where it interacts with 
Nod2 and activates the cells [22, 41]. Thus, monocytes/macrophages activation by 
L-MTP-PE is considered to be mediated via Nod2 [16, 21] (Figure 2). In sum, preclinical 
studies showed that L-MTP-PE, in comparison with free MTP-PE, was more effective in 
terms of activating monocytes [22], was longer held in target organs [32], and was 
10-fold less toxic [42].  
Monocytes activated by L-MTP-PE had no effect on non-tumorigenic cells  [24, 
26, 43] and even under conditions of co-cultivation with tumorigenic cells [24, 43]. 
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Furthermore, peripheral blood monocytes from patients with cancer could be activated to 
similar levels of tumoricidal activity as monocytes from healthy volunteers [26, 39, 43, 
44]. L-MTP-PE interacts with interferon (IFN)-γ to up-regulate tumoricidal activity and 
to induce secretion of cytokines such as TNF-α and IL-1β [21, 45-50]. The mechanism of 
this potentiation remains to be elucidated, but a 2-fold increase in liposome phagocytosis 
was observed after treatment of human monocytes with IFN-γ   [50]. 
Activation of monocytes-mediated tumoricidal activity was investigated 
following in vivo treatment with L-MTP-PE in phase I and II clinical trials [36, 51, 52]. In 
the phase I study, 28 patients with metastatic cancer received increasing doses (1h 
intravenous administration) of L-MTP-PE (0.05-12.0 mg/m2) twice a week [36, 51]. 
Peripheral blood monocytes were harvested and examined ex vivo for cytotoxic activity 
against human A375 melanoma cells before L-MTP-PE therapy and at various time 
points during the 9-week treatment period. Activation of monocytes-mediated cytotoxic 
activity was seen in 24 (86%) of the 28 patients at some time points during the treatment 
period [51]. Monocytes-mediated tumoricidal activity remained for up to 96 hours after 
initial mifamurtide infusion [36]. In the phase II study, 16 patients with relapsed 
osteosarcoma received a 1h intravenous infusion of L-MTP-PE (2 mg/m2) twice a week 
for 12 weeks [52]. These patients had histologically confirmed osteosarcoma and 
Page 9 of 33
URL: http://mc.manuscriptcentral.com/eoop  Email: Elizabeth.Knowles@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
10 
 
pulmonary metastases that had developed during adjuvant chemotherapy or that were 
present at diagnosis and had persisted despite chemotherapy. The patients were 
pre-treated with surgical resection of visible and palpable lung metastases before 
participating in the study. Peripheral blood monocytes were harvested and examined ex 
vivo for cytotoxic activity against human A375 melanoma cells before L-MTP-PE 
therapy and during the 4-week treatment period. Monocytes-mediated tumoricidal 
activity was significantly increased in 80% of the patients evaluated. The peak cytotoxic 
activity was observed at 24 (n = 3), 72 (n = 4), and 96 (n = 1) hours post-infusion [52]. 
Similarly, monocytes and macrophages from non-human species demonstrated increased 
tumoricidal activity after in vitro [25, 28] and in vivo [28, 46, 53-55] treatment with 
L-MTP-PE or MTP-PE.       
Although various chemotherapeutic agents and regimens have been examined 
for osteosarcoma, none of them demonstrates any clear superiority [15, 56]. Since 
L-MTP-PE was intended to be used in combination with both adjuvant chemotherapy 
and surgery in the treatment of osteosarcoma, some researchers reported the effects of 
cytotoxic agents on the monocytes-mediated tumoricidal activity of L-MTP-PE [39, 57, 
58]. These results showed that most chemotherapeutic drugs including the treatment of 
osteosarcoma (i.e., doxorubicin, cisplatin, high-dose methotrexate with leucovorin rescue, 
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and ifosfamide) did not influence on macrophage activation by L-MTP-PE [39, 57, 58].  
For example, doxorubicin [39, 57], cisplatin  [39], methotrexate [39], or 
cyclophosphamide [39] administration to patients with osteosarcoma did not interfere 
with the ability of L-MTP-PE to enhance the monocytes-mediated tumoricidal activity 
from these patients in vitro. Furthermore, combination chemotherapy of doxorubicin and 
cyclophosphamide strongly suppressed monocytes-mediated tumoricidal activity by 
L-MTP-PE [39]. Similarly, simultaneous administration of ifosfamide and L-MTP-PE 
did not interfere with the ability of L-MTP-PE to activate an in vivo immune response 
according to the results of a phase IIb clinical study in patients with relapsed 
osteosarcoma (n = 9) [58]. The trial participants had histologically confirmed 
osteosarcoma and pulmonary metastases that had developed during adjuvant 
chemotherapy or that were present at diagnosis and had persisted despite chemotherapy. 
They were treated neoadjuvantly and/or adjuvantly with a combination of ifosfamide (up 
to 8 cycles in total; each cycle consisted of 1.8 g/m2 for 5 days every 21 days) and 
L-MTP-PE (2 mg/m2 twice a week for 12 weeks and then once a week for 12 weeks). 
Up-regulations of serum TNF-α, IL-6, and IL-8 in patients treated with the combination 
therapy was not different from those in patients treated with L-MTP-PE alone [52]. In 
addition, monocytes-mediated tumoricidal activity was elevated at 24 and 72 hours after 
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the initial of combination therapy, similar to the following L-MTP-PE alone [51]. In 
particular, combination treatment of ifosfamide and L-MTP-PE did not increase the 
toxicity of ifosfamide [58]. L-MTP-PE did not decrease the tumoricidal activity of 
ifosfamide or doxorubicin in three synergistic murine tumor models [59]. Furthermore, 
the suggested course of L-MTP-PE therapy did not worsen the identified renal (i.e., 
cisplatin, ifosfamide) or hepatic (i.e., methotrexate, ifosfamide) toxicities of the 
concurrently administered chemotherapies in phase III study in patients with 
osteosarcoma [60].   
 
3. Clinical therapeutic efficacy  
A phase III randomized prospective trial was conducted by the Children’s Cancer and 
Pediatric Oncology Groups (now collectively known as the Children’s Oncology Group) 
from 1993 to 1997 [12]. This central randomized trial in osteosarcoma was known as 
the Intergroup Study 0133 (INT study 0133). A total of 662 eligible patients aged ≤ 
30 years with non-metastatic resectable osteosarcoma were employed in this study 
[17]. This study was designed to assess whether the addition of L-MTP-PE and/or 
ifosfamide to a standard chemotherapeutic regimen composed of three agents (i.e., 
doxorubicin, cisplatin and high-dose methotrexate with leucovorin rescue) would 
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increase both EFS and overall survival in newly diagnosed patients with high-grade 
osteosarcoma. No significant improvement in EFS and overall survival was observed by 
the addition of ifosfamide in the dose and schedule used in this study (p = 0.934 and 0.992 
respectively). However, significant improvement in EFS and overall survival were 
observed in patients randomized to receive L-MTP-PE (p = 0.030 and 0.039 respectively). 
These findings correspond to a 25% reduction in the risk of recurrence and a 30% 
reduction in the risk of death [21, 61]. Most notably, the 6-year overall survival improved 
from 70% without L-MTP-PE to 78% with it [17]. 
In the INT study 0133, all patients were intended to receive a similar backbone 
treatment called MAP (i.e., high-dose methotrexate with leucovorin rescue, 
doxorubicin/adriamycin, and cisplatin) with identical cumulative doses of high-dose 
methotrexate (12 times at doses of 12 g/m2), doxorubicin (6 times at doses of 75 mg/m2), 
and cisplatin (4 times at doses of 120 mg/m2). The randomized prospective study was 
conducted with a 2 × 2 factorial design with 4 treatment groups: (1) MAP, (2) MAP + 
L-MTP-PE, (3) MAP + ifosfamide, and (4) MAP + ifosfamide + L-MTP-PE. Ifosfamide 
was administered 5 times at a dose of 9 g/m2 per course. L-MTP-PE was administered at 
a dose of 2 mg/m2 in the adjuvant setting. L-MTP-PE was administered intravenously 
twice a week for 12 weeks starting at week 12, and then weekly for additional 24 weeks 
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starting at week 24. The duration of treatment was 20 weeks for patients randomly 
assigned to ‘MAP’ group, 27 weeks for patients randomly assigned to ‘MAP + 
ifosfamide’ group, and 36 weeks for patients randomly assigned to ‘MAP + L-MTP-PE’ 
group and ‘MAP + ifosfamide + L-MTP-PE’ [12, 17]. The results of INT study 0133 
were analyzed and published in 2005 and 2008 [12, 17]. In 2005, Meyers et al. [12] 
reported their initial analysis of EFS without overall survival. According to their findings, 
there was no significant evidence of L-MTP-PE on EFS [12]. Later, this initial report was 
cited as inappropriate analyses. In 2008, both overall survival and EFS were renewed 
as the result of subsequent analysis of this study with longer follow-up [17]. This 
re-analysis reported improved overall survival with the addition of L-MTP-PE from 70% 
to 78% 6-year overall survival (p = 0.03) [17]. By contrast, in the analysis of EFS, there 
was no sufficient evidence of the interaction (p = 0.102) [17]. This makes the 
interpretation of INT 0133 study very complicated [62, 63] because the effect of 
treatment on overall survival is expected to be mediated through EFS. There were no 
differences in the frequency of favorable tumor necrosis, which is strongly associated 
with EFS and determined by modified Huvos grading [64], among those treatment groups. 
Therefore, the authors concluded that ifosfamide and the other chemotherapy agents are 
equivalent in their ability to contribute to favorable tumor necrosis. Furthermore, another 
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study demonstrated that patients with metastatic osteosarcoma were given a good benefit 
by administration of a higher dose of ifosfamide (14 mg/m2) [65, 66] . Thus, the most 
effective combination of ifosfamide with L-MTP-PE may be a dose question. At any rate, 
many additional questions including the best way to combine chemotherapy and 
L-MTP-PE still remain, but the INT study 0133 demonstrated the possible benefit 
associated with L-MT -PE in the treatment of osteosarcoma.  
 
4. Dosage and Side effects after premedication 
In European Union, L-MTP-PE is indicated in patients with high-grade, 
resectable, non-metastatic osteosarcoma after the complete surgical wide resection 
aged between 2 and 30 years [60]. It is currently recommended that L-MTP-PE is 
intravenously-administered over 1 hour twice weekly for an initial 12 weeks, followed by 
once weekly for an additional 24 weeks (total 48 infusions in 36 weeks) [17]. Since all 
patients recently receiving L-MTP-PE on a compassionate basis have had evidence of 
biologic activity at 2 mg/m2, premedication and use of the fixed 2 mg/m2 dose is 
suggested. The preparation and infusion of L-MTP-PE has recently been validated in 
numerous processes, and these are reproducible and easily performed in the outpatient 
setting. 
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L-MTP-PE therapy was generally well tolerated [36, 67]. The most commonly 
reported side effects are listed in Figure 3. Most of those side effects were severe [60]. 
In the phase I and II studies, there was no evidence of dose-dependent [68], cumulative 
[36], and organ-related [68] toxicity in association with L-MTP-PE. Furthermore, the 
majority of patients experienced side effects with the initial administration of the agent 
[36, 69]. The major side effects of L-MTP-PE administration are fever and chills. They 
are typically transient and generally respond to the treatment [60]. The possibility of 
anti-inflammatory drugs relieving these adverse effects has been investigated. 
Premedication such as ibuprofen [70] can help prevent the severity of fever and chills. 
However, high-dose ibuprofen (> 40 µg/ml) with L-MTP-PE down-regulates the 
antitumor effect and the production of IL-1 and TNF-α in monocytes [70]. The antitumor 
effect of L-MTP-PE was lost in a murine fibrosarcoma model using diclofenac [71]. 
These findings suggest that anti-inflammatory agents such as cyclooxygenase inhibitors 
can down-regulate the antitumor effect of L-MTP-PE. For ibuprofen-resistant cases, 
acetaminophen and/or meperidine are recommended as alternative agents [13]. 
Specifically, ibuprofen 200 or 400 mg is given as a premedication, If fever and/or chills 
occur, acetaminophen (15 mg/kg; up to 1000mg) may be given. If needed more, both 
acetaminophen and ibuprofen may be additionally utilized to improve the symptoms [17, 
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72].  
 
5. Expert Opinion 
The orphan disease limits the number of patients available to study. 
Osteosarcoma is an orphan disease with fewer than 1500-2000 new cases per year 
diagnosed in the USA similar to Europe. Indeed, except L-MTP-PE, only IFN-α study are 
undergoing as international cooperative trial for osteosarcoma adjuvant chemotherapy. 
The efficacy of IFN-α, which is initiated after postoperative chemotherapy, is 
investigated by EURAMOS 1 [40]. Unfortunately, this trial is still under the recruitment 
phase [19]. Therefore, L-MTP-PE, the first new agent approval for the treatment of 
osteosarcoma in over 20 years, is strongly expected to become ‘routine’ for both 
oncologists and patients with osteosarcoma. Information about potential benefit 
regarding mifamurtide use in the neoadjuvant setting (i.e. before surgery) and/or utility of 
L-MTP-PE in metastatic in relapsed and metastatic osteosarcoma will require analysis of 
expanded access and/or future clinical trials of L-MTP-PE in high burden and low burden 
situations. 
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Figure legends 
Figure 1: The molecular structure of liposomal muramyl tripeptide phosphatidyl 
ethanolamine (L-MTP-PE). 
Figure 2: Nod2 is an intracellular MDP sensor. Monocytes/macrophages activation by 
L-MTP-PE is mediated via Nod2. L-MTP-PE is selectively phagocytosed by monocytes 
and macrophages after intravenous administration. L-MTP-PE is released into the cytosol 
and degraded to MDP. Nod2 binding to MDP activates NF-κB and influences the innate 
immune response [41]. Abbreviations: Nod2; nucleotide-binding oligomerization 
domain 2, MDP; muramyl dipeptide, L-MTP-PE; liposomal muramyl tripeptide 
phosphatidyl ethanolamine, NF-κB; nuclear factor-kappa B. 
Figure 3: Tolerability of mifamurtide. Major side effects in 248 patients with advanced 
cancer including 51 patients with osteosarcoma [36, 59, 66-68]. 
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Drug Summary Box 
 
 
Drug name Mifamurtide  
Phase Launched 
Launched indication osteosarcoma 
Pharmacology description Macrophage stimulant 
Route of administration Parenteral, intravenous 
Chemical structure C59H109N6O19P 
Pivotal trial(s) Phase III 
 
 
Pharmaprojects - copyright to Citeline Drug Intelligence (an Informa business). Readers are 
referred to Pipeline (http://informa-pipeline.citeline.com) and Citeline 
(http://informa.citeline.com).  
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